William Benton Jones

CIK: 0001664506

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (33.3%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CRVS

Corvus Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

CRVS
Corvus Pharmaceuticals, Inc.
Dec 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
400K shares-
CRVS
Corvus Pharmaceuticals, Inc.
Jun 4, 2025
Exercise(M)
Direct
19.4K shares at avg. $3.50$68K
CRVS
Corvus Pharmaceuticals, Inc.
Dec 20, 2024
Award(A)
Stock Option (Right to Buy)
Direct
300K shares-

		Type	Shares	Price		Ownership
Dec 4, 2025	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	400,000	-	-	Direct
Jun 4, 2025	CRVS Corvus Pharmaceuticals, Inc.	Exercise(M)	19,357	$3.50	$67,750	Direct
Dec 20, 2024	CRVS Corvus Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	300,000	-	-	Direct

1-3 of 3 transactions

About Jones William Benton

Jones William Benton (SEC CIK 0001664506) files insider reports with the SEC as Officer of Corvus Pharmaceuticals, Inc. (CRVS).

Signal8 holds 3 ownership filings by Jones William Benton, all Form 4s, filed between Dec 23, 2024 and Dec 8, 2025. Those filings report 3 transactions, from Dec 20, 2024 to Dec 4, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Jones William Benton's filings is in BURLINGAME, CA.

Recent filings by Jones William Benton

Dec 4, 2025: Grant or award of CRVS derivative securities (Form 4, code A).
Jun 4, 2025: Option exercise of CRVS shares (Form 4, code M).
Dec 20, 2024: Grant or award of CRVS derivative securities (Form 4, code A).

Other insiders filing for Corvus Pharmaceuticals, Inc. (CRVS)

Moore David Scott, Director
CLARK IAN T, Director
Grais Linda, Director
Thompson Peter A., Director
van den Broek Richard, Director
MILLER RICHARD A MD, President and CEO

How to read Form 4 transaction codes